JP2025504955A5 - - Google Patents
Info
- Publication number
- JP2025504955A5 JP2025504955A5 JP2024544969A JP2024544969A JP2025504955A5 JP 2025504955 A5 JP2025504955 A5 JP 2025504955A5 JP 2024544969 A JP2024544969 A JP 2024544969A JP 2024544969 A JP2024544969 A JP 2024544969A JP 2025504955 A5 JP2025504955 A5 JP 2025504955A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- amino acid
- acid sequence
- seq
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263305003P | 2022-01-31 | 2022-01-31 | |
| US63/305,003 | 2022-01-31 | ||
| US202263309759P | 2022-02-14 | 2022-02-14 | |
| US63/309,759 | 2022-02-14 | ||
| US202263342283P | 2022-05-16 | 2022-05-16 | |
| US63/342,283 | 2022-05-16 | ||
| US202263348842P | 2022-06-03 | 2022-06-03 | |
| US63/348,842 | 2022-06-03 | ||
| PCT/EP2023/052366 WO2023144423A1 (en) | 2022-01-31 | 2023-01-31 | Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504955A JP2025504955A (ja) | 2025-02-19 |
| JP2025504955A5 true JP2025504955A5 (cg-RX-API-DMAC7.html) | 2026-02-06 |
Family
ID=85199086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544969A Pending JP2025504955A (ja) | 2022-01-31 | 2023-01-31 | 活性化可能な二重特異的抗ｃｄ４７および抗ｐｄ－ｌ１タンパク質ならびにその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250002585A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4473012A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025504955A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240137084A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023210844A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251615A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314395A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009251A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023144423A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| CN111212852A (zh) | 2017-08-18 | 2020-05-29 | 超人肆有限公司 | 结合剂 |
| US20240124889A1 (en) * | 2019-05-07 | 2024-04-18 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| CN116390939A (zh) * | 2020-08-04 | 2023-07-04 | 埃克塞里艾克西斯公司 | 多重特异性结合剂及其用途 |
-
2023
- 2023-01-31 CA CA3251615A patent/CA3251615A1/en active Pending
- 2023-01-31 AU AU2023210844A patent/AU2023210844A1/en active Pending
- 2023-01-31 IL IL314395A patent/IL314395A/en unknown
- 2023-01-31 EP EP23703706.4A patent/EP4473012A1/en active Pending
- 2023-01-31 MX MX2024009251A patent/MX2024009251A/es unknown
- 2023-01-31 WO PCT/EP2023/052366 patent/WO2023144423A1/en not_active Ceased
- 2023-01-31 KR KR1020247028692A patent/KR20240137084A/ko active Pending
- 2023-01-31 JP JP2024544969A patent/JP2025504955A/ja active Pending
-
2024
- 2024-07-19 US US18/778,061 patent/US20250002585A1/en active Pending